

P.O. BOX 31577 Tampa, FL 33631-3577

## **UPDATE**

12/02/2024

## 'Ohana QUEST Integration Medicaid Preferred Drug List

Dear Provider,

At the **December 2<sup>nd</sup> 2024** WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes will be made to the **'Ohana QUEST Integration Medicaid Preferred Drug List** (PDL), effective **03/01/2025**. Please carefully review these changes.

| Key                                  |                               |  |  |
|--------------------------------------|-------------------------------|--|--|
| UPPER CASE = Brand Name Drugs        | QL = Quantity Limit           |  |  |
| Lower case italics = Generic Drugs   | ST = Step Therapy             |  |  |
| PDL = Preferred Drug List            | AL = Age Limit                |  |  |
| PA = Prior Authorization             | YOA = Years of Age            |  |  |
| SC = Safety Concerns                 | <b>LU</b> = Low Utilization   |  |  |
| PC = Pharmacoeconomic Considerations | <b>DD</b> = Discontinued Drug |  |  |
| GA = Generic Available               | CR = Clinical Removal         |  |  |

Effective Date: 03/01/2025

| Drug Name            | Therapeutic<br>Class | Change                   | PDL Alternative (if applicable) |  |  |
|----------------------|----------------------|--------------------------|---------------------------------|--|--|
| ADDITIONS TO THE PDL |                      |                          |                                 |  |  |
| lisdexamfetamine     | Attention Deficit-   | Added to PDL with PA     |                                 |  |  |
| chewable tablets     | Hyperactivity        | and QL/DD of 1; Modify   |                                 |  |  |
| (Vyvanse)            | Disorder (ADHD)      | Medicaid PA criteria     |                                 |  |  |
|                      | Therapy              | (CP.PMN.121) to          |                                 |  |  |
|                      |                      | remove the redirection   |                                 |  |  |
|                      |                      | of chewable tablets to   |                                 |  |  |
|                      |                      | regular capsules. Add    |                                 |  |  |
|                      |                      | the redirection of brand |                                 |  |  |
|                      |                      | Vyvanse products         |                                 |  |  |
|                      |                      | through                  |                                 |  |  |
|                      |                      | lisdexamfetamine         |                                 |  |  |
|                      |                      | generics to criteria.    |                                 |  |  |



P.O. BOX 31577 Tampa, FL 33631-3577

| lisdexamfetamine tablets | Attention Deficit-    | Added to PDL with PA;        |  |  |  |  |
|--------------------------|-----------------------|------------------------------|--|--|--|--|
| (Vyvanse)                | Hyperactivity         | Modify Medicaid PA           |  |  |  |  |
| (vyvanse)                | Disorder (ADHD)       | criteria (CP.PMN.121) to     |  |  |  |  |
|                          | Therapy               | remove the redirection       |  |  |  |  |
|                          | ····c· ap y           | of chewable tablets to       |  |  |  |  |
|                          |                       | regular capsules. Add        |  |  |  |  |
|                          |                       | the redirection of brand     |  |  |  |  |
|                          |                       | Vyvanse products             |  |  |  |  |
|                          |                       | through                      |  |  |  |  |
|                          |                       | lisdexamfetamine             |  |  |  |  |
|                          |                       | generics to criteria.        |  |  |  |  |
|                          | REMOVALS FROM THE PDL |                              |  |  |  |  |
| Unbranded Novolog        | Novo Nordisk          | Removed from PDL             |  |  |  |  |
| (insulin aspart)         | Rapid-Acting and      | nemorea nem 22               |  |  |  |  |
| (modim dopart)           | Basal Insulins        |                              |  |  |  |  |
|                          | Basar msamis          |                              |  |  |  |  |
| Unbranded Tresiba        | Novo Nordisk          | Removed from PDL;            |  |  |  |  |
| (insulin degludec)       | Rapid-Acting and      | Retire Tresiba Medicaid      |  |  |  |  |
| (msaim degrades)         | Basal Insulins        | prior authorization          |  |  |  |  |
|                          | Dasai ilisalilis      | criteria (CP.PMN.285) to     |  |  |  |  |
|                          |                       | default the class to the     |  |  |  |  |
|                          |                       | non-formulary criteria.      |  |  |  |  |
| U <sup>*</sup>           | TII IZATION MANA      | AGEMENT CHANGES              |  |  |  |  |
| Trulicity (dulaglutide)  | Diabetic Therapy      | PA updated; Add              |  |  |  |  |
| Victoza (liraglutide)    | - GLP-1 Receptor      | minimum age of 10 years      |  |  |  |  |
| a seed a (in agrantic)   | Agonists              | to Trulicity and             |  |  |  |  |
|                          | 7.80111363            | authorized generic           |  |  |  |  |
|                          |                       | liraglutide products         |  |  |  |  |
|                          |                       | (Liraglutide AGs) in HI      |  |  |  |  |
|                          |                       | Medicaid.                    |  |  |  |  |
| Lumakras (sotorasib)     | Antineoplastics -     | PA updated; Add              |  |  |  |  |
| Krazati (adagrasib       | KRAS Inhibitors       | redirection from Krazati     |  |  |  |  |
| Mazati (adagrasib        |                       | to Lumakras for non-         |  |  |  |  |
|                          |                       | small cell lung cancer       |  |  |  |  |
|                          |                       | indication (NSCLC) in        |  |  |  |  |
|                          |                       | patients without             |  |  |  |  |
|                          |                       | metastasis to the brain in   |  |  |  |  |
|                          |                       | the initial criteria section |  |  |  |  |
|                          |                       | (CP.PHAR.605).               |  |  |  |  |
|                          |                       | (CI .I TIAN.003).            |  |  |  |  |



P.O. BOX 31577 Tampa, FL 33631-3577

If you have questions, 'Ohana Health Plan's Pharmacy Help Desk is available to assist providers at **1-888-846-4262**.

Thank you for your care of 'Ohana Medicaid members.

Sincerely, 'Ohana Health Plan Pharmacy

'Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc.